{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-035262","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.137075+00:00","generated_at":"2026-05-31T12:06:49.377023+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cumberland Pharma Q2 revenue $9.9M, up 16% sequentially; adjusted earnings positive","bullets":["Q2 net revenue $9.9M, 16% increase from Q1 2024; year-to-date $18.3M.","Adjusted earnings $0.2M ($0.01/share), a $0.8M improvement vs prior Q1 period.","Net loss $1.1M ($0.08/share) in Q2; year-to-date net loss $3.0M ($0.21/share).","Product revenue: Kristalose $4.1M, Vibativ $2.5M, Sancuso $2.2M, Caldolor $0.8M in Q2.","Cash $17.3M; $16.1M drawn on credit line; total assets $78.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-035262","json":"https://secwatch.observer/filing/0001628280-24-035262.json","markdown":"https://secwatch.observer/filing/0001628280-24-035262.md","text":"https://secwatch.observer/filing/0001628280-24-035262.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000162828024035262/0001628280-24-035262-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000162828024035262/cpix-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:06:49.377023+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}